# Purinostat

Source: https://onco.cc/drugs/purinostat/  
OnCo record `purinostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Purinostat is an experimental investigational agent whose form is not stated in the registry from Chengdu Zenitar Biomedical Technology in phase 3 trials for diffuse large B-cell lymphoma and multiple myeloma, with its target not yet stated publicly.

## Summary

Purinostat is an investigational agent whose form is not stated in the registry developed by Chengdu Zenitar Biomedical Technology. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: The subjects in the experimental group will receive treatment with Purinostat Mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous infusion on days 1, 4, 8, and 11. The administration cycle las. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07011056 (A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma), in diffuse large B-cell lymphoma and multiple myeloma. The largest, NCT07011056, plans to enrol 390 participants with primary completion expected 2029-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Purinostat Mesylate
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Purinostat: https://clinicaltrials.gov/search?intr=Purinostat

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- trials: [A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06431243/), [A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma](https://onco.cc/trials/nct06485219/), [A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct07011056/), [Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06484829/)
- companies: [Chengdu Zenitar Biomedical Technology](https://onco.cc/companies/chengdu-zenitar-biomedical-technology/)

---
JSON: https://onco.cc/api/v1/entities/purinostat.json